Exobiosphere’s platform is designed to remove barriers for scientists by delivering data faster, with greater consistency and scale that is feasible in orbit, while also boosting terrestrial lab productivity.

Researchers will study how microgravity affects organoid growth to model diseases and test drugs, potentially revealing faster growth or different development in space.

Experiments will be conducted aboard Haven-1 to explore how reduced gravity influences organoid development.

Cedars-Sinai is partnering with Exobiosphere to conduct biomedical research aboard Haven-1, Vast’s planned commercial space station, with a focus on organoid growth in microgravity using automated hardware.

The research aims to identify therapies for astronaut health issues—bone and muscle loss, heart and immune system degradation—with potential terrestrial applications for conditions like sarcopenia, osteoporosis, and cardiomyopathy.

Cedars-Sinai Accelerator+ and Cedars-Sinai Technology Ventures have backed Exobiosphere with a $1.4 million investment and ongoing mentorship to bring space-based bioscience research to market.

The collaboration builds on Cedars-Sinai work showing surface tension in 96-well plates can retain contents in microgravity, enabling ground-based hardware to be used in space research and democratizing life sciences.

The collaboration aims to accelerate biomedical research in space and translate findings to Earth, leveraging Exobiosphere’s compact, automated platform for organoid experimentation.

Exobiosphere provides a six-plate, compact automated system for space-based organoid work, featuring precision liquid handling, environmental control, robotic manipulation, live imaging, an incubator, and a robotic arm.

The platform integrates six 96-well plates with built-in incubator, microfluidic liquid dispenser, plate reader, and robotic arm, optimized for microgravity and Earth-based lab efficiency.

Spokespeople emphasize advancing space biomedicine and translating space research into Earth-based healthcare, with potential long-term impacts on therapies for astronauts and patients.